vrs
BMS Partnering
From this source:
Partnering plays a strategic role in executing our R&D strategy, evolving our portfolio and growth. Our goal in partnering is to discover, develop and deliver transformational medicines to patients by bringing innovative science, research and technology together with our capabilities and expertise.
And:
External innovation and partnering are critical drivers of out strategy and have brought significant commercial success and pipeline growth. 60% of our current development pipeline is externally sourced and 12 of our 20 blockbuster drugs are derived from collaborations.
So the interest from BMS is based on fact. It appears that they would be open to the notion that Veyonda could indeed be a transformational medicine.
- Forums
- ASX - By Stock
- NOX
- BMS NOX to partner on pilot study
BMS NOX to partner on pilot study, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.06M |
Open | High | Low | Value | Volume |
12.0¢ | 12.0¢ | 11.5¢ | $5.653K | 48.83K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 22101 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 159073 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 22101 | 0.115 |
2 | 75461 | 0.110 |
4 | 445000 | 0.105 |
6 | 244077 | 0.100 |
1 | 6000 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 159073 | 5 |
0.125 | 144133 | 5 |
0.130 | 409378 | 5 |
0.135 | 205000 | 2 |
0.140 | 227281 | 6 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online